Sodium glycerophosphate

Sodium glycerophosphate
Clinical data
Trade names	Glycophos
AHFS/Drugs.com	Professional Drug Facts
Pregnancy; category	AU: Exempt;
Routes of; administration	Intravenous infusion
ATC code	B05XA14 (WHO) ;
Legal status
Legal status	AU: Unscheduled;
Identifiers
	IUPAC name disodium 3-(phosphonooxy)propane-1,2-diol;
CAS Number	1334-74-3 ; 55073-41-1 ;
PubChem CID	22251426;
DrugBank	DB09561;
ChemSpider	14071;
UNII	YP1H63LJ2K; RCS9EQ01V4;
KEGG	D10489;
ChEMBL	ChEMBL3040581;
Chemical and physical data
Formula	C3H7Na2O6P
Molar mass	216.036 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	98 to 100 °C (208 to 212 °F)
Solubility in water	very soluble
	SMILES [Na+].[Na+].OCC(O)COP([O-])([O-])=O;
	InChI InChI=1S/C3H9O6P.2Na/c4-1-3(5)2-9-10(6,7)8;;/h3-5H,1-2H2,(H2,6,7,8);;/q;2*+1/p-2; Key:GEKBIENFFVFKRG-UHFFFAOYSA-L; Key:OFNNKPAERNWEDD-UHFFFAOYSA-L;

Sodium glycerophosphate, sold under the brand name Glycophos, is a medication used to supplement phosphate. It is administered via intravenous infusion.

Sodium glycerophosphate is an organic phosphate salt.

It was approved for medical use in Australia in November 2019.

It is an unapproved medication in the United States that was used as a substitute for inorganic phosphate during a drug shortage.